Global Markets Direct’s, 'Mild Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mild Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Pain. Mild Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Mild Pain. - A review of the Mild Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mild Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mild Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mild Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Mild Pain - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Mild Pain Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Mild Pain 6 Mild Pain Therapeutics under Development by Companies 8 Pre-Clinical Stage Products 9 Comparative Analysis 9 Mild Pain Therapeutics - Products under Development by Companies 10 Companies Involved in Mild Pain Therapeutics Development 11 Nektar Therapeutics 11 Immupharma Plc 12 Mild Pain - Therapeutics Assessment 13 Assessment by Monotherapy Products 13 Assessment by Route of Administration 14 Assessment by Molecule Type 16 Drug Profiles 18 NKTR-194 - Drug Profile 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 IPP-102199 - Drug Profile 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 Mild Pain Therapeutics - Dormant Products 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 22 Disclaimer 22
List of Tables
Number of Products Under Development for Mild Pain, H1 2013 6 Products under Development for Mild Pain - Comparative Analysis, H1 2013 7 Number of Products under Development by Companies, H1 2013 8 Comparative Analysis by Pre-Clinical Stage Development, H1 2013 9 Products under Development by Companies, H1 2013 10 Nektar Therapeutics, H1 2013 11 Immupharma Plc, H1 2013 12 Assessment by Monotherapy Products, H1 2013 13 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Stage and Molecule Type, H1 2013 17 Mild Pain Therapeutics - Dormant Products 20
List of Figures
Number of Products under Development for Mild Pain, H1 2013 6 Products under Development for Mild Pain - Comparative Analysis, H1 2013 7 Products under Development by Companies, H1 2013 8 Pre-Clinical Stage Products, H1 2013 9 Assessment by Monotherapy Products, H1 2013 13 Assessment by Route of Administration, H1 2013 14 Assessment by Stage and Route of Administration, H1 2013 15 Assessment by Molecule Type, H1 2013 16 Assessment by Stage and Molecule Type, H1 2013 17